We believe that adherence to endocrine therapies is a subject that will increasingly be given the concerted attention it deserves. We expect that quality-of-life issues will continue to gain prominence alongside disease-oriented outcomes in the minds of both healthcare providers and the patients themselves as information becomes increasingly accessible. We expect to see advancements in the therapies, with new therapies under investigation that carry lesser side-effect profiles, while simultaneously being more efficacious. In addition, we believe that interventions will be developed to ensure more efficacious management of side effects and obstacles to adherence. We are confident that these new developments will help address the barriers that prevent women from receiving the optimal care available to them.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(6):709-715. © 2011 Expert Reviews Ltd.